K2 MEDICAL RESEARCH | PRESS RELEASE
Global Phase III study is investigating whether intervening against Alzheimer’s disease biology before cognitive symptoms emerge can delay or prevent progression to symptomatic disease
ORLANDO, Fla. — September 2026 — K2 Medical Research today announced that it has begun screening participants for PrevenTRON, Roche’s global Phase III study evaluating investigational trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease who are at high risk of progressing to symptomatic disease.
K2 was among just three sites activated worldwide at the launch of the global study — two in the United States and one in Canada. K2 and one other U.S. research center began screening participants on the first day, placing K2 among the first sites in the world to begin screening for this landmark Alzheimer’s prevention study.
The milestone marks the beginning of an ambitious global effort to answer one of the most important questions in Alzheimer’s research:
Can we intervene against the biology of Alzheimer’s disease before memory loss and other cognitive symptoms begin?
“This is exactly why we built K2,” said Sean Stanton, CEO and Co-Founder of K2 Medical Research. “For decades, Alzheimer’s research has largely begun after a person or their family noticed that something was wrong. PrevenTRON asks whether we can move that starting line — identify the biology earlier and investigate whether intervening before symptoms begin can change what happens next.”
“This represents a profound shift in how we think about Alzheimer’s disease research,” said Brandon Lenox, DO, MPH, Co-Founder, Chief Medical Officer and Head of Operations at K2 Medical Research. “Historically, we have largely studied Alzheimer’s disease after cognitive symptoms have emerged. PrevenTRON moves the scientific question earlier — to people who are cognitively unimpaired but have biomarkers associated with Alzheimer’s disease pathology. We are now asking whether intervening against that biology before symptoms develop can delay or prevent progression to symptomatic Alzheimer’s disease.”
PrevenTRON represents a fundamentally earlier approach to Alzheimer’s research. Rather than waiting for memory loss or other symptoms to develop, the study is designed to identify cognitively unimpaired individuals who have biological evidence associated with Alzheimer’s disease and evaluate whether intervening at this preclinical stage can alter progression toward symptomatic disease.
Potential participants are initially evaluated using a blood-based biomarker, pTau217, which can help identify people with a higher likelihood of amyloid pathology associated with Alzheimer’s disease. Individuals who meet initial criteria may then choose whether they wish to proceed with additional study evaluation. Participation at every stage is voluntary.
“The ability to begin this process with a blood-based biomarker is incredibly important,” Lenox continued. “It gives researchers a practical way to identify people who may be appropriate for further evaluation without assuming they have Alzheimer’s disease or committing them to a clinical trial. They can learn about the research, understand their options and decide whether participation is right for them. Ultimately, volunteers are what make answering this scientific question possible.”
“We are incredibly proud of our team, but even more grateful to the people who volunteer to participate,” said Sheila Baez-Torres, MD, MBA, Principal Investigator at K2 Medical Research. “They are the reason this research is possible, and it is a privilege to help bring this science closer to patients and families.”
A Global Effort to Move Alzheimer’s Research Earlier
PrevenTRON is evaluating trontinemab, Roche’s investigational Brainshuttle™ amyloid-beta-targeting monoclonal antibody.
In earlier clinical research involving people with Alzheimer’s disease, Roche reported rapid and substantial reductions in brain amyloid plaques with trontinemab. PrevenTRON takes the scientific question one step earlier: whether targeting Alzheimer’s pathology in cognitively unimpaired people at high risk of clinical decline can ultimately delay or prevent progression to symptomatic disease.
The study is part of a major international scientific effort involving leading research centers and investigators around the world.
At the launch of PrevenTRON, three sites worldwide were activated to begin screening — two in the United States and one in Canada. Two U.S. sites, including K2 Medical Research, screened participants on the study’s first day.
“Being among the first sites in the world to begin screening is an extraordinary accomplishment for our team, but the significance is much larger than K2,” Stanton said. “This is a global effort to answer a question that could fundamentally change how we approach Alzheimer’s disease. Alzheimer’s does not recognize borders. Progress will come from researchers, physicians, companies and, most importantly, volunteers around the world willing to participate in the science.”
K2 Seeking Volunteers for Alzheimer’s Prevention Research
K2 Medical Research will be actively screening potential participants for PrevenTRON over the coming months.
The research is intended for people who are cognitively unimpaired — individuals who are not currently experiencing the cognitive impairment associated with Alzheimer’s disease — but who may have biological evidence that places them at increased risk of developing symptomatic disease.
For potential volunteers, the first step is an evaluation to determine whether they may be appropriate for further screening. Those who qualify can then decide whether they want to continue through the study evaluation process.
Participation is entirely voluntary.
Study eligibility requirements apply, space is limited, and qualified participants may receive reimbursement for time and study-related expenses in accordance with the study protocol and applicable regulations.
“We are asking people in our communities to consider doing something extraordinary,” Stanton said. “Alzheimer’s disease is one person away from virtually every one of us — a parent, spouse, friend or eventually ourselves. The breakthroughs we all want will not happen without people willing to participate in research.”
“Every major advance in medicine has depended on someone being willing to go first. We are incredibly proud of the individuals who have raised their hands and of the K2 team that made our first-day screening possible. Now we need others to step forward with us.”
About PrevenTRON
PrevenTRON is a global Phase III clinical study sponsored by Hoffmann-La Roche evaluating the efficacy and safety of investigational trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease who are at high risk of clinical decline.
Roche is using its Elecsys® pTau217 blood test to help identify potential study participants.
Trontinemab is an investigational medicine and has not been approved by the U.S. Food and Drug Administration for the prevention or treatment of Alzheimer’s disease. It has not been established that trontinemab prevents Alzheimer’s disease or prevents cognitive decline. The PrevenTRON study is designed to investigate these questions.
Participation in a clinical trial does not guarantee clinical benefit.
About K2 Medical Research
K2 Medical Research is an integrated clinical research organization dedicated to advancing the development of new medicines through high-quality clinical trials and community-based access to research.
K2 has made a significant long-term commitment to Alzheimer’s disease and neurodegenerative research, working to bring advanced clinical studies closer to the patients, families and communities affected by these diseases.
Interested in Alzheimer’s Prevention Research?
K2 Medical Research will be evaluating potential volunteers for the PrevenTRON study over the next six months.
Individuals who are cognitively unimpaired and interested in learning more about Alzheimer’s prevention research are encouraged to contact K2 Medical Research to determine whether they may be appropriate for evaluation.
Participation is voluntary. Eligibility requirements apply. Space is limited. Qualified participants may receive reimbursement for time and study-related expenses.
Media Contact
K2 Medical Research
Beth Ann Williams
813-448-1633
Beth.Williams@k2med.com
k2med.com
